Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | FPR1 | P21462 | 3/20 | 0.40 |
| ▸ | FPR2 | P25090 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3073452 | 0.86 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1EPHX2 | |
| SCHEMBL3085694 | 0.85 | LMNA (0.43) | KMT2AALDH1A1LMNARAB9AGAA | |
| SCHEMBL3074739 | 0.84 | KDM1A (0.46) | ALDH1A1LMNARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6043165 | 0.82 | REN (0.46) | KMT2AMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL6042204 | 0.82 | ALDH1A1 (0.54) | KMT2AMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL3070134 | 0.82 | LMNA (0.41) | KMT2AMEN1ALDH1A1LMNAGAA | |
| SCHEMBL6041580 | 0.81 | REN (0.45) | KMT2AMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL6042033 | 0.81 | REN (0.45) | KMT2AMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL3064737 | 0.81 | REN (0.49) | — | |
| SCHEMBL3072743 | 0.81 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | KMT2A 3839/4885MEN1 2817/4885ALDH1A1 142/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | KMT2A 3839/4885MEN1 2817/4885ALDH1A1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.